Source: BioPharma-Reporter

Abzena: Abzena's advanced drug development showcased at CPHI Milan

At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
250-500
Matthew Stober's photo - CEO of Abzena

CEO

Matthew Stober

CEO Approval Rating

82/100

Read more